Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial
Authors:
- 18 March 2019
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 31 (2) , 141-146
Abstract
Background: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, has shown superiority to ustekinumab (UST) and etanercept in skin clearance from randomized clinical trials in patients with moderate-to-severe psoriasis [1,2]. Objective: To compare cumulative benefits of IXE versus UST over 52 weeks of treatment. Methods: Cumulative clinical benefit of IXE and UST was assessed by evaluating the AUC for responders of PASI, itch NRS, and DLQI outcomes over 52 weeks using data from IXORA-S trial [2] comparing IXE (N = 136) and UST (N = 166). Normalized cumulative benefit was calculated to obtain the percentage of the maximum AUC for each outcome measure. Missing values were imputed using nonresponder imputation. Results: Significantly greater cumulative benefits were obtained for IXE compared with UST. Normalized cumulative benefit with IXE versus UST for PASI 75/90/100, Itch NRS (0), and DLQI (0,1) were 83.1% and 67.6%; 68.9% and 46.5%; 41.1% and 23.4%; 40.4% and 30.9%; and 62.2% and 46.6%, respectively. Cumulative clinical benefit ratios for IXE:UST were 1.23 for PASI 75, 1.48 for PASI 90, and 1.76 for PASI 100, indicating an increase in the cumulative clinical benefit for IXE versus UST as the clearance levels increased. Conclusions: IXE showed greater cumulative clinical benefit than UST.Keywords
Funding Information
- Eli Lilly and Company
This publication has 12 references indexed in Scilit:
- Treatment Approaches to Moderate to Severe PsoriasisInternational Journal of Molecular Sciences, 2017
- Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyBritish Journal of Dermatology, 2017
- Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasisJournal of Dermatological Treatment, 2016
- Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17AJournal of Inflammation Research, 2016
- Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del pacienteActas Dermo-Sifiliograficas, 2014
- Cumulative Life Course Impairment: Evidence for Psoriasis2013
- Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life courseBritish Journal of Dermatology, 2011
- Psoriasis: is the impairment to a patient’s life cumulative?Journal of the European Academy of Dermatology and Venereology, 2010
- Psoriasis and its managementBMJ, 2006
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994